CO4980847A1 - Procesos para estabilizar macrolidos de polieno y un macrolido obtenido en forma cristalina - Google Patents

Procesos para estabilizar macrolidos de polieno y un macrolido obtenido en forma cristalina

Info

Publication number
CO4980847A1
CO4980847A1 CO99074905A CO99074905A CO4980847A1 CO 4980847 A1 CO4980847 A1 CO 4980847A1 CO 99074905 A CO99074905 A CO 99074905A CO 99074905 A CO99074905 A CO 99074905A CO 4980847 A1 CO4980847 A1 CO 4980847A1
Authority
CO
Colombia
Prior art keywords
macrolide
antioxidant
process according
rapamycin
polyene
Prior art date
Application number
CO99074905A
Other languages
English (en)
Spanish (es)
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4980847(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4980847A1 publication Critical patent/CO4980847A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CO99074905A 1998-12-07 1999-11-29 Procesos para estabilizar macrolidos de polieno y un macrolido obtenido en forma cristalina CO4980847A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
CO4980847A1 true CO4980847A1 (es) 2000-11-27

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99074905A CO4980847A1 (es) 1998-12-07 1999-11-29 Procesos para estabilizar macrolidos de polieno y un macrolido obtenido en forma cristalina

Country Status (38)

Country Link
US (5) US6605613B2 (enExample)
EP (4) EP1743657A3 (enExample)
JP (3) JP3805625B2 (enExample)
KR (2) KR20060096477A (enExample)
CN (2) CN1261163C (enExample)
AR (3) AR026102A1 (enExample)
AT (1) ATE365051T1 (enExample)
AU (1) AU759219B2 (enExample)
BE (1) BE1012869A3 (enExample)
BR (1) BR9915986A (enExample)
CA (3) CA2651609A1 (enExample)
CO (1) CO4980847A1 (enExample)
CY (1) CY1106870T1 (enExample)
CZ (2) CZ303006B6 (enExample)
DE (1) DE69936352T3 (enExample)
DK (1) DK1137439T4 (enExample)
ES (1) ES2288033T5 (enExample)
FR (1) FR2786771B1 (enExample)
GB (2) GB9826882D0 (enExample)
HK (1) HK1038889B (enExample)
HU (2) HU228939B1 (enExample)
ID (1) ID29250A (enExample)
IL (1) IL143092A0 (enExample)
IT (1) IT1319701B1 (enExample)
MY (2) MY120594A (enExample)
NO (2) NO332698B1 (enExample)
NZ (2) NZ511936A (enExample)
PE (1) PE20001333A1 (enExample)
PL (2) PL208854B1 (enExample)
PT (1) PT1137439E (enExample)
RU (1) RU2243769C2 (enExample)
SG (1) SG151072A1 (enExample)
SI (1) SI1137439T2 (enExample)
SK (2) SK286688B6 (enExample)
TR (2) TR200101416T2 (enExample)
TW (2) TWI270550B (enExample)
WO (1) WO2000033878A2 (enExample)
ZA (1) ZA200104360B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
CA2475383C (en) 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
KR20050114262A (ko) * 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005010015A1 (en) 2003-07-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Method of purifying macrolides
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
JP2007520262A (ja) * 2003-12-10 2007-07-26 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 経皮または局所薬物輸送に伴う副作用の処置方法
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2006039237A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
AR058283A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
JP2009520818A (ja) * 2005-12-20 2009-05-28 ワイス 薬物物質不純物の制御によるｃｃｉ−７７９製剤安定性の制御
CN101605529B (zh) * 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
WO2011156025A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline Ezatiostat Hydrochloride Ansolvate
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (enExample) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
US20190015513A1 (en) * 2015-08-28 2019-01-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) * 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
EP1266900A1 (en) 1992-10-13 2002-12-18 Wyeth Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
ATE228135T1 (de) * 1995-06-09 2002-12-15 Novartis Erfind Verwalt Gmbh Rapamycinderivate
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
JP2001511780A (ja) 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物

Also Published As

Publication number Publication date
US6852729B2 (en) 2005-02-08
TWI270550B (en) 2007-01-11
WO2000033878A3 (en) 2000-11-02
ES2288033T3 (es) 2007-12-16
KR20010101128A (ko) 2001-11-14
HK1038889B (en) 2008-01-25
CN1374872A (zh) 2002-10-16
US7741338B2 (en) 2010-06-22
DE69936352D1 (de) 2007-08-02
CA2651609A1 (en) 2000-06-15
US7572804B2 (en) 2009-08-11
US7297703B2 (en) 2007-11-20
SK287325B6 (sk) 2010-07-07
TWI248938B (en) 2006-02-11
JP5165199B2 (ja) 2013-03-21
EP1743657A2 (en) 2007-01-17
EP1137439B1 (en) 2007-06-20
SI1137439T2 (sl) 2012-05-31
PT1137439E (pt) 2007-09-25
KR20060096477A (ko) 2006-09-11
AR048073A2 (es) 2006-03-29
HU230174B1 (hu) 2015-09-28
EP1137439B2 (en) 2011-11-23
JP3805625B2 (ja) 2006-08-02
AR026102A1 (es) 2003-01-29
CA2351580C (en) 2012-03-20
JP2006111637A (ja) 2006-04-27
WO2000033878A2 (en) 2000-06-15
EP2269651A2 (en) 2011-01-05
JP2005200429A (ja) 2005-07-28
MY120594A (en) 2005-11-30
EP1743657A3 (en) 2007-03-28
US20050107418A1 (en) 2005-05-19
HUP0104489A2 (hu) 2002-03-28
US20020032213A1 (en) 2002-03-14
NZ527781A (en) 2004-11-26
FR2786771B1 (fr) 2002-12-27
NO20012424D0 (no) 2001-05-16
IT1319701B1 (it) 2003-10-27
CN1261163C (zh) 2006-06-28
ATE365051T1 (de) 2007-07-15
SK286688B6 (sk) 2009-03-05
CA2732620A1 (en) 2000-06-15
AU1657300A (en) 2000-06-26
DE69936352T2 (de) 2008-02-14
US20090270441A1 (en) 2009-10-29
ID29250A (id) 2001-08-16
GB9826882D0 (en) 1999-01-27
HUP0104489A3 (en) 2004-05-28
IL143092A0 (en) 2002-04-21
CN1876657B (zh) 2013-01-09
DE69936352T3 (de) 2012-05-03
HK1038889A1 (en) 2002-04-04
DK1137439T4 (da) 2012-03-19
PL208854B1 (pl) 2011-06-30
NO20121113L (no) 2001-05-16
PE20001333A1 (es) 2000-12-12
ITMI992520A1 (it) 2001-06-02
AR054444A2 (es) 2007-06-27
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
HU228939B1 (en) 2013-07-29
EP1137439A2 (en) 2001-10-04
JP5043308B2 (ja) 2012-10-10
CZ20012001A3 (cs) 2001-09-12
NO332698B1 (no) 2012-12-10
US6605613B2 (en) 2003-08-12
NO334612B1 (no) 2014-04-22
CZ302210B6 (cs) 2010-12-22
PL348333A1 (en) 2002-05-20
PL196627B1 (pl) 2008-01-31
FR2786771A1 (fr) 2000-06-09
EP2279751A2 (en) 2011-02-02
ES2288033T5 (es) 2012-04-10
EP2269651A3 (en) 2011-03-09
US20080161334A1 (en) 2008-07-03
BR9915986A (pt) 2001-09-04
SI1137439T1 (sl) 2008-06-30
NZ511936A (en) 2003-10-31
TR200101416T2 (tr) 2002-01-21
SG151072A1 (en) 2009-06-29
KR100695834B1 (ko) 2007-03-19
MY127579A (en) 2006-12-29
CZ303006B6 (cs) 2012-02-22
SK7662001A3 (en) 2001-12-03
US20030191148A1 (en) 2003-10-09
CN1876657A (zh) 2006-12-13
GB9904934D0 (en) 1999-04-28
RU2243769C2 (ru) 2005-01-10
CA2732620C (en) 2013-08-06
BE1012869A3 (fr) 2001-04-03
NO20012424L (no) 2001-05-16
ITMI992520A0 (it) 1999-12-02
TR200201428T2 (tr) 2002-12-23
CA2351580A1 (en) 2000-06-15
JP2002531527A (ja) 2002-09-24
TW200540179A (en) 2005-12-16
AU759219B2 (en) 2003-04-10
EP2279751A3 (en) 2011-02-16
ZA200104360B (en) 2002-01-16

Similar Documents

Publication Publication Date Title
CO4980847A1 (es) Procesos para estabilizar macrolidos de polieno y un macrolido obtenido en forma cristalina
Ha et al. Peroxide formation in polysorbate 80 and protein stability
ES2183782T3 (es) Material de sutura para heridas a base de metilideno malonato.
BRPI0415409A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
DK0463969T3 (da) Hidtil ukendte 4-aminosmørsyreforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske præparater, som indeholder dem
ZA200005098B (en) Method for stabilizing pharmaceutical compositions by special use of an antioxidant.
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
ES2164265T3 (es) Unidades monomericas utiles para reducir el modulo de hidrogeles de silicona.
BR0017013A (pt) Composições de antibiótico azalìdeo
ES2113844T3 (es) Composiciones fitoactivas liquidas y metodos de uso.
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
AR040226A1 (es) Productos parenterales antifungicos
NO20060631L (no) Fast dispersjon av takrolimus
CY1110261T1 (el) Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα
MX2024010625A (es) Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
MX2021011376A (es) Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
BR112014006608A2 (pt) formulações com base em dispersões sólidas
AR042910A1 (es) Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen
ATE373466T1 (de) Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
GT200200032A (es) Nuevo sistema estabilizador para estabilizacion de polimeros halogenados
DK1534352T3 (da) Implantat til transport og afgivelse af farmakologisk aktive midler såvel som en fremgangsmåde til fremstilling af samme
AR046768A1 (es) Derivados de piridin-tetrazol, metodos de obtencion y composiciones farmaceuticas
KR900016456A (ko) 유로키나제 선구물질의 안정화방법 및 무수조성물
ITSA20030013A1 (it) Manufatti microporosi e nanoporosi a base di